DDS (Drug Delivery System) is a technology that
delivers a drug.
This technology can reduce the dose or the number of administrations, which means that it can lessen the burden on patients by enhancing the efficacy of a drug while ameliorating any side effects.
Development period for DDS products are reduced in comparison with the standard period of time for new drug development
For pharmaceutical products already launched, a part of study processes required for development of general pharmaceutical products can be skipped. As with DR products explained separately, this enables quick, cost-effective, certain development of safe pharmaceutical products.
While PEGylation technology is popular as DDS technology for protein pharmaceuticals, our company is the only one that possesses the technology to improve the pharmacokinetics of protein by lecithinization. (The clinical trial of PC-SOD based on this technology is ongoing.) This technology can be applicable for other protein pharmaceuticals.
Unlike previous DDS carriers focusing on either of targeting or controlled-release, our stealth-type polymeric nanoparticles are the world’s first DDS carrier successfully achieving both of them. In addition to nano-PGE1 and nano-BPS (beraprost sodium) currently under development, it is possible to encapsulate other drugs into this original DDS carrier.
Encapsulating drugs in lipid emulsions allows drug pharmacokinetics to be improved. We, as the pioneer in this technology, have successfully launched lipo-PGE1 and lipo-NSAID into the market. Our partner, Beijing Tide Pharmaceutical has one of the world’s biggest manufacturing plants for lipid emulsion pharmaceuticals.
To date, 19 liposome products have already been launched all over the world. Encapsulating various drug substances, including anti-cancer drug substances and nucleic acids, in liposome (including lipid nanoparticles) enables the passive targeting and active targeting of the targeted tissues or cells. Our representative for this technology (head of the Shonan Institute), who has been engaged in DDS research, such as liposome, in other companies for more than 38 years, has various accomplishments and experience in mass production, stability assurance, production of investigational products, regulatory actions, and collaborative development of pharmaceutical and cosmetic products with many companies in Japan, the USA, and Europe.
An example of liposome product containing a typical anti-cancer substance